3.1.1. 18–60 Age Cohort
SARS-COV-2 INFECTION
The study profile in the 18–60 age cohort is presented in Two out of three hundred participants from the Vaccine Group withdrew consent prior to the administration of the 1st dose. Thus, a safety assessment was performed on 398 (298 in the Vaccine Group and 100 in the Placebo Group) participants of the study. Participants who contracted SARS-CoV-2 infection during the observation period were not excluded from the safety assessment.Out of 200 (150 in the Vaccine Group and 50 in the Placebo Group) participants initially included in Stage 3 for immunogenicity assessment, a total of 33 (28 from the Vaccine Group and 5 from the Placebo Group) were excluded during the observation period as they contracted SARS-CoV-2 infection or withdrew consent. Thus, an immunogenicity assessment was performed on 167 (122 in the Vaccine Group and 45 in the Placebo Group) participants of Stage 3.The demographic characteristics of the participants in the safety and immunogenicity assessment populations were similar across treatment groups in terms of sex, age, and mean body mass index (BMI) (